Hong Kong Life Sciences and Technologies Lim : company information sheet

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

FF003G

APPENDIX 5 FORMS RELATING TO LISTING FORM F THE GROWTH ENTERPRISE MARKET (GEM) COMPANY INFORMATION SHEET

Case Number:

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name:	Hong Kong Life Sciences and Technologies Group Limited
Stock code (ordinary shares):	8085

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 6 January 2017

1. General

   Place of incorporation:	Cayman Islands
   Date of initial listing on GEM:	7 March 2002
   Name of Sponsor(s):	N/A
   Names of directors: (please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive)	Executive Directors Mr. David Lin Kao Kun (Vice Chairman) Mr. Lu Zhiqiang (Chief Executive Officer) Mr. Chui Kwong Kau Mr. Jiang Hongqing Ms. Li Mei Non-executive Director Ms. Lam Kuo (Chairman) Independent Non-executive Directors Mr. Hung Yat Ming Mr. Chan Yun Hing Mr. Gui Qiangfang

   Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	Name Number of Approximate ordinary shares percentage of held issued share capital Mr. David Lin Kao Kun 878,862,333 15.45%
   Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:	N/A
   Financial year end date:	31 March
   Registered address:	Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands British West Indies
   Head office and principal place of business:	Unit 2704, 27/F., West Tower Shun Tak Centre 168-200 Connaught Road Central Hong Kong
   Web-site address (if applicable):	www.hklifesciences.com
   Share registrar:	Principal share registrar and transfer office in the Cayman Islands: Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor, Royal Bank House 24 Shedden Road, George Town Grand Cayman KY1-1110 Cayman Islands Branch share registrar and transfer office in Hong Kong: Tricor Standard Limited Level 22, Hopewell Centre 183 Queen's Road East Hong Kong
   Auditors:	Pan-China (H.K.) CPA Limited

2. Business activities

   The Company is an investment holding company. The Company and its subsidiaries are principally engaged in (i) anti-aging and stem cell technology businesses; (ii) trading business; (iii) money lending business; and (iv) securities investment.

3. Ordinary shares

   Number of ordinary shares in issue:	5,688,396,805
   Par value of ordinary shares in issue:	HK$0.04
   Board lot size (in number of shares):	4,000
   Name of other stock exchange(s) on which ordinary shares are also listed:	N/A

4. Warrants

   Stock code:	N/A
   Board lot size:
   Expiry date:
   Exercise price:
   Conversion ratio: (Not applicable if the warrant is denominated in dollar value of conversion right)
   No. of warrants outstanding:
   No. of shares falling to be issued upon the exercise of outstanding warrants:

5. Other securities

Details of any other securities in issue.

N/A

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:
(Sd.)	(Sd.)
Lam Kuo	David Lin Kao Kun
(Sd.)	(Sd.)
Lu Zhiqiang	Chui Kwong Kau
(Sd.)	(Sd.)
Jiang Hongqing	Li Mei
(Sd.)	(Sd.)
Hung Yat Ming	Chan Yun Hing
(Sd.)
Gui Qiangfang

NOTES

1. This information sheet must be signed by or pursuant to a power of attorney for and on behalf of each of the Directors of the Company.

2. Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet, together with a hard copy duly signed by or on behalf of each of the Directors, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

3. Please send a copy of this form by facsimile transaction to Hong Kong Securities Clearing Company Limited (on 2815-9353) or such other number as may be prescribed from time to time) at the same time as the original is submitted to the Exchange.